NasdaqGS - Nasdaq Real Time Price USD

Jazz Pharmaceuticals plc (JAZZ)

109.94

+0.67

(+0.61%)

At close: 4:00 PM EDT

110.75

+0.81

(+0.74%)

After hours: 4:20 PM EDT

Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 first quarter financial results on Wednesday, May 1, 2024, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2024 first quarter financial results and provide a business and financial update.

PR Newswire 2 days ago

JAZZ
+0.61%
Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 13 abstracts from across its neuroscience portfolio and pipeline, including two oral presentations, will be featured at the 76th Annual American Academy of Neurology Meeting (AAN) being held April 13-18, 2024, in Denver.

PR Newswire 9 days ago

JAZZ
+0.61%
Pharma Stock Roundup: AZN Voydeya Gets FDA Nod, MRK KRAS Inhibitor Enters Phase III

FDA approves AstraZeneca's (AZN) Voydeya (danicopan) in the United States as add on therapy to its other C5 inhibitors. Merck (MRK) begins a phase III study on its oral KRAS G12C inhibitor candidate.

Zacks 14 days ago

AZN

JAZZ
+0.61%
Following the Money Trail: Where are Hedge Funds Investing?

For years, investors have chased the latest tech darlings, throwing money at overvalued companies based on hype and empty promises. At Insider Monkey we do things a little bit different. We focus our attention on not stock promoters but seasoned hedge fund managers and shrewd corporate insiders. We pay attention when informed executives and smart […]

Insider Monkey 15 days ago

WAT

VIRT

PYPL
Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for the HER2-targeted bispecific antibody zanidatamab as a treatment for previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC). If approved, zanidatamab would be the first HER2-targeted treatment specifically approved fo

PR Newswire 17 days ago

JAZZ
+0.61%
Why Is Jazz (JAZZ) Up 1.3% Since Last Earnings Report?

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 21 days ago

JAZZ
+0.61%
UTHR
+0.42%
Cancer and the Combination Approach

Oncology is a tricky sector in which to innovate, but we can start by optimizing existing combination approaches NORTHAMPTON, MA / ACCESSWIRE / March 28, 2024 / Jazz Pharmaceuticals By Liz Henderson Liz Henderson, Sr. Vice President Technical Operations ...

ACCESSWIRE 22 days ago

JAZZ
+0.61%
Jazz Pharmaceuticals Celebrates International Women’s Day

NORTHAMPTON, MA / ACCESSWIRE / March 20, 2024 / Jazz Pharmaceuticals Originally published by Jazz Pharmaceuticals To mark International Women's Day, JAWS (Jazz Association of Women Supporters), the affinity forum created to promote the advancement ...

ACCESSWIRE 30 days ago

JAZZ
+0.61%
20 States with the Cheapest Weed in America

In this article, we are going to discuss the 20 states with the cheapest weed in America. You can skip our detailed analysis of the cannabis industry in America, the effect of legalization on prices, and the budding cannabis-based pharmaceutical industry, and go directly to the 5 States with the Cheapest Weed in America. In […]

Insider Monkey last month

PFE

JAZZ
+0.61%
30 Biggest Biotechnology Companies in the World

In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World. In the ever-evolving landscape of biotechnology, several companies like Novo Nordisk, Regeneron, and United […]

Insider Monkey last month

ILMN

AZN

EXEL
+0.13%
Exploring How Jazz Pharmaceuticals Honored U.S. Black History Month

NORTHAMPTON, MA / ACCESSWIRE / March 14, 2024 / Jazz Pharmaceuticals Originally published by Jazz Pharmaceuticals on LinkedIn In honor of U.S. Black History Month, JazzSoul, the affinity forum created to support Black employees and their allies and ...

ACCESSWIRE last month

JAZZ
+0.61%
Unlocking Jazz Pharmaceuticals' Potential: A Roadmap for Growth

A closer look at one of the leaders in the global narcolepsy therapeutics market

GuruFocus.com last month

JAZZ
+0.61%
7 Biotech Stocks to Buy as Sector Rotation Ramps Up

While the technology sector has been enjoying ridiculous returns, it’s inevitable that a slowdown (or even a correction) may materialize, which brings to the table biotech stocks. This is just as innovative of sector as “regular” tech but it just hasn’t received the same fervor. That could soon change. With the usual suspects in the digital innovation arena soaring to new heights, the law of large numbers will eventually kick in. For investors to get the same rewards they’ve been used to will li

InvestorPlace last month

CYTK

CRSP

VKTX
11 Stocks Insiders are Buying Now

In this article, we will take a detailed look at the 11 Stocks Insiders are Buying Now. For a quick overview of such stocks, read our article 5 Stocks Insiders are Buying Now. Despite a hotter-than-expected CPI report, the stock market remained in the green on March 12, which is a good sign according to many analysts as investors […]

Insider Monkey last month

ABSI

CECO

^GSPC
Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host a virtual R&D Day, Tuesday, March 19, from 8:00 a.m. to 10:00 a.m. ET, focused on zanidatamab, a differentiated, bispecific antibody in late-stage development with the potential to transform the standard of care in multiple HER2-positive cancers. The webcast will highlight the mechanistic rationale and clinical data that support further development of zanidatamab as a treatment for biliary tract cancer (BTC), gastroesophageal adenocarcinoma (GEA)

PR Newswire last month

JAZZ
+0.61%
Jazz Pharmaceuticals (NASDAQ:JAZZ) shareholders have endured a 32% loss from investing in the stock three years ago

As an investor its worth striving to ensure your overall portfolio beats the market average. But the risk of stock...

Simply Wall St. last month

JAZZ
+0.61%
Q4 2023 Zymeworks Inc Earnings Call

Q4 2023 Zymeworks Inc Earnings Call

Thomson Reuters StreetEvents last month

BGNE

JAZZ
+0.61%
10 Mid-Cap Stocks with Insider Purchases

In this article, we will take a detailed look at the 10 Mid-Cap Stocks with Insider Purchases. For a quick overview of such stocks, read our article 5 Mid-Cap Stocks with Insider Purchases. Investors are yet again in a wait-and-see mode ahead of key jobs and inflation numbers, but the overall sentiment in the market is positive, helped […]

Insider Monkey last month

ALLE

AMN

ADC
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q4 2023 Earnings Call Transcript

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q4 2023 Earnings Call Transcript February 28, 2024 Jazz Pharmaceuticals plc misses on earnings expectations. Reported EPS is $5.02 EPS, expectations were $5.26. Jazz Pharmaceuticals plc isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, […]

Insider Monkey last month

JAZZ
+0.61%
Here's What Key Metrics Tell Us About Jazz (JAZZ) Q4 Earnings

The headline numbers for Jazz (JAZZ) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks last month

JAZZ
+0.61%

Performance Overview

Return	JAZZ	S&P 500
YTD	-10.62%	+4.14%
1-Year	-23.42%	+19.55%
3-Year	-34.91%	+18.68%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Jazz Pharmaceuticals plc (JAZZ)

Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024

Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting

Pharma Stock Roundup: AZN Voydeya Gets FDA Nod, MRK KRAS Inhibitor Enters Phase III

Following the Money Trail: Where are Hedge Funds Investing?

Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer

Why Is Jazz (JAZZ) Up 1.3% Since Last Earnings Report?

Cancer and the Combination Approach

Jazz Pharmaceuticals Celebrates International Women’s Day

20 States with the Cheapest Weed in America

30 Biggest Biotechnology Companies in the World

Exploring How Jazz Pharmaceuticals Honored U.S. Black History Month

Unlocking Jazz Pharmaceuticals' Potential: A Roadmap for Growth

7 Biotech Stocks to Buy as Sector Rotation Ramps Up

11 Stocks Insiders are Buying Now

Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024

Jazz Pharmaceuticals (NASDAQ:JAZZ) shareholders have endured a 32% loss from investing in the stock three years ago

Q4 2023 Zymeworks Inc Earnings Call

10 Mid-Cap Stocks with Insider Purchases

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q4 2023 Earnings Call Transcript

Here's What Key Metrics Tell Us About Jazz (JAZZ) Q4 Earnings

Performance Overview